Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.
about
Update on Hepatitis B Virus Infection: Focus on TreatmentLamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in PatientsStealing the Keys to the Kitchen: Viral Manipulation of the Host Cell Metabolic NetworkDifferential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virusAssociation between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapyIn Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein.Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia.Emerging antiviral resistant strains of influenza A and the potential therapeutic targets within the viral ribonucleoprotein (vRNP) complex.Hepatitis B virus: new therapeutic perspectives.In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses.Unveiling the roles of HBV polymerase for new antiviral strategiesBroad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in GabonModeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction.Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development.Present and future therapies of hepatitis B: From discovery to cureEvaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultra‑deep pyrosequencing.The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to AdefovirChronic hepatitis B: A wave of new therapies on the horizon.HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data MiningAn update on the strategies used for the treatment of chronic hepatitis B in children.Emerging drugs for the treatment of hepatitis B.Review article: novel therapies for hepatitis B virus cure - advances and perspectives.Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B.Escape of tick-borne flavivirus from 2' -C-methylated nucleoside antivirals is mediated by a single conservative mutation in NS5 that has a dramatic effect on viral fitness.Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase.New horizon for radical cure of chronic hepatitis B virus infection.Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitorsSerum viral duplex-linear DNA proportion increases with the progression of liver disease in patients infected with HBV.A comparative study on the characterization of hepatitis B virus quasispecies by clone-based sequencing and third-generation sequencing.Modulation of Lipid Droplet Metabolism-A Potential Target for Therapeutic Intervention in Flaviviridae Infections.Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.Drugs in Development for Hepatitis B.Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses.
P2860
Q26781990-D0EBD661-278A-49B2-B37E-0BB1E0BC525FQ27468616-221C0CCC-2E6E-4972-A36C-967301D3C65AQ28084730-17A19E54-C44C-4C92-883C-F544DDE71A62Q28542705-660F3B93-B639-4E0B-A8A0-BDE10B40E9E2Q30390865-25F51457-45A0-40B5-9B19-26D43BC27C1DQ33753964-821D174E-F76C-46FF-894F-003FFA87B80FQ33883921-506319E2-E24E-4B97-B8A0-8F34227653F4Q34269400-42E260B9-D151-4420-B98E-5795092A9510Q34507250-E7FFC618-B852-4D4F-A209-863F94893E6BQ34519919-93E7980F-2FD9-454D-8256-4FAA460BAEA0Q35441503-46C339F7-3E04-4587-8B56-A35991C648AEQ35893639-276E9CF6-0D96-434C-AB15-B8E1D1C8842CQ36120901-87377951-52F3-4AFB-8861-8827C38D8DFBQ36264766-AFE0C6DE-A18B-4885-AD2C-3BEA311C69A6Q36378278-048D43DE-A240-4B17-949B-3F8844EC40B6Q36390330-E243C2BB-50FC-4175-B0E6-809188DE1F0CQ36805368-45489227-01AF-49BA-B62B-2347395C07C5Q38538107-E69EA06F-B32E-4953-8C53-94D037B7660FQ38657888-DA20928D-958F-46DD-91A7-8173F7E2BC9FQ38692198-2705D648-B281-4DA6-BC48-255136CAC265Q38759805-D9062D84-E177-48C3-A926-E6D8E7414471Q38865511-E54E0F46-30D2-47A1-B90A-986671271980Q39018635-40E841AB-B425-48C5-BD60-523850503E23Q40080931-88852886-6B21-491A-94B2-CE387FAEEB80Q40180055-4345255A-A3E0-43D0-9FB2-22F423DD4464Q40593364-DC9F532B-DA1C-4E23-B928-EA795677A62FQ40798098-022074EE-4377-496D-99D7-0AC7926D4363Q41183859-3D189164-77B9-4139-AFE9-595DF547E5E7Q45325133-51707DF3-AE01-4D74-89F1-4DBF08CD5F2CQ47104952-47A3399B-4729-4657-B2A3-B7782F8A5076Q47556623-75C0E3C1-0727-41F6-B884-98251B7D73DDQ47890590-93BA26F6-C40A-4716-B57E-FE4D222D6E9FQ52764230-4556F2D8-396F-42F7-8713-AFB4B20B804DQ54256710-42AB9777-C77B-4C42-9411-15F278163A8A
P2860
Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Nucleoside/nucleotide analog i ...... nism of action and resistance.
@en
type
label
Nucleoside/nucleotide analog i ...... nism of action and resistance.
@en
prefLabel
Nucleoside/nucleotide analog i ...... nism of action and resistance.
@en
P2093
P50
P1476
Nucleoside/nucleotide analog i ...... anism of action and resistance
@en
P2093
Beatriz Pacheco
Luis Menéndez-Arias
Mar Álvarez
P356
10.1016/J.COVIRO.2014.04.005
P577
2014-05-09T00:00:00Z